Analysis Reveals Why COVID Pneumonia Is Extra Lethal


TUESDAY, Jan. 12, 2021 (HealthDay Information) — In contrast to common pneumonia, COVID-19 pneumonia spreads like many “wildfires” all through the lungs, researchers say.

This may occasionally clarify why COVID-19 pneumonia lasts longer and causes extra hurt than typical pneumonia, in accordance with the researchers at Northwestern Medication in Chicago.

The analysis crew mentioned that their goal is to make COVID-19 extra like a foul chilly.

For the research, the crew analyzed immune cells from the lungs of COVID-19 pneumonia sufferers and in contrast them to cells from sufferers with pneumonia brought on by different viruses or micro organism.

Whereas different types of pneumonia quickly infect giant areas of the lungs, COVID-19 begins in quite a few small areas of the lungs. It then makes use of the lungs’ personal immune cells to unfold throughout the lungs over many days and even weeks. That is much like how a number of wildfires unfold by means of a forest, the research authors defined.

As COVID-19 pneumonia slowly strikes by means of the lungs, it leaves broken lung tissue in its wake and contributes to the fever, low blood pressure and organ injury frequent in COVID-19 sufferers, the crew mentioned.

The lengthy period of COVID-19 pneumonia, moderately than larger severity, could also be why it causes extra severe issues than different sorts of pneumonia, in accordance with the research authors. The report was revealed on-line Jan. 11 within the journal Nature.

The researchers additionally recognized immune cells — macrophages and T cells — that may very well be essential targets when treating extreme COVID-19 pneumonia. Macrophages usually shield the lungs, however will be contaminated by the new coronavirus and assist unfold the an infection by means of the lungs, the crew famous in a Northwestern information launch.

In a scientific trial early this yr, the investigators plan to check an experimental drug that targets these immune cells in COVID-19 pneumonia sufferers. The drug reduces the inflammatory response of those immune cells.

“Our objective is to make COVID-19 delicate as an alternative of extreme, making it akin to a foul chilly,” research co-author Dr. Scott Budinger mentioned within the information launch. He’s chief of pulmonary and demanding care medication at Northwestern College Feinberg College of Medication.

Examine co-author Dr. Richard Wunderink, professor of pulmonary and demanding care medication at Feinberg and medical director of Northwestern Medication’s ICU, added that “this effort actually represents a ‘moonshot’ in COVID-19 analysis.”

Extra info

The U.S. Facilities for Illness Management and Prevention has extra on COVID-19.

SOURCE: Northwestern Medication, information launch, Jan. 11, 2021